Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems

• Published in: Drug discovery today 2020-12, Vol.25 (12), p.2212-2226
• Main Authors: Rapalli, Vamshi Krishna, Waghule, Tejashree, Gorantla, Srividya, Dubey, Sunil Kumar, Saha, Ranendra Narayan, Singhvi, Gautam
• Format: Article
• Language: English
• ISSN: 1359-6446; 1878-5832
• DOI: 10.1016/j.drudis.2020.09.023

•Psoriasis pathogenesis involved cytokines, microbial peptides, genetic disposition.•Psoriasis is autoimmune disorder that affects approximately 125 million population.•The new small targeted therapies JAK inhibitors, RORγt inhibitors are in pipeline.•The advanced drug delivery can improve the efficacy of the existing therapeutics. Psoriasis is a chronic autoimmune skin disorder triggered by either genetic factors, environmental factors, life style, or a combination thereof. Clinical investigations have identified pathogenesis, such as T cell and cytokine-mediated, genetic disposition, antimicrobial peptides, lipocalin-2, galectin-3, vaspin, fractalkine, and human neutrophil peptides in the progression of psoriasis. In addition to traditional therapies, newer therapeutics, including phosphodiesterase type 4 (PDE4) inhibitors, Janus kinase (JAK) inhibitors, monoclonal antibodies (mAbs), gene therapy, anti-T cell therapy, and phytoconstituents have been explored. In this review, we highlight nanotechnology-related developments for psoriasis treatment, including patented delivery systems and therapeutics currently in clinical trials. The manuscript elaborates on recent findings in pathogenesis, new therapies and advanced drug delivery systems for improved treatment of psoriasis.